Differences in weight reduction efficacy of tirzepatide in adults without versus with type 2 diabetes with overweight or obesity in SURMOUNT 1 and 2

Diabetologie und Stoffwechsel 2025; 20(S 01): S101
DOI: 10.1055/s-0045-1807559

Abstracts | DDG 2025

Poster

Posterwalk 15: Sonstige Themen

Authors

R J Galindo

¹University of Miami Miller School of Medicine, Medicine, Miami, Florida, United States
W T Garvey

²UAB Diabetes Research Center, University of Alabama at Birmingham, Nutrition Sciences, Birmingham, AL, United States
L M Neff

³Eli Lilly and Company, Global Medical Affairs-Obesity, Indianapolis, United States
A Stefanski

⁴Eli Lilly and Company, CWM Development, Indianapolis, United States
D Cao

⁵Eli Lilly and Company, Statistics, Indianapolis, United States
C Lee

⁶Eli Lilly and Company, Obesity/NILEX, Indianapolis, United States
T Forst

⁷CRS Clinical Research Services, CRS Clinical Research Services, Mannheim, Germany